Pro Historical Income Statement

PME Stock

251.89 3.71 1.49%

Historical analysis of Pro Medicus income statement accounts such as EBIT of 117.9 M, Ebitda of 126.8 M, Total Operating Expenses of 9.6 M or Income Before Tax of 122.3 M can show how well Pro Medicus performed in making a profits. Evaluating Pro Medicus income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Pro Medicus's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Pro Medicus latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Pro Medicus is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pro Medicus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Pro Income Statement Analysis

Pro Medicus Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Pro Medicus shareholders. The income statement also shows Pro investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Pro Medicus Income Statement Chart

At this time, Pro Medicus' Net Income is comparatively stable compared to the past year. Income Tax Expense is likely to gain to about 35.4 M in 2024, whereas Total Operating Expenses is likely to drop slightly above 9.6 M in 2024.

Other Operating Expenses Ebitda Total Operating Expenses Net Income

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Pro Medicus. It is also known as Pro Medicus overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Pro Medicus financial statement analysis. It represents the amount of money remaining after all of Pro Medicus operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Most accounts from Pro Medicus' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Pro Medicus current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pro Medicus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	7.9M	8.5M	10.1M	9.6M
EBITDA	70.4M	94.1M	120.8M	126.8M

Total Operating Expenses Ebitda

Pro Medicus income statement Correlations

	Depreciation And Amortization	Interest Expense	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Total Revenue	Cost Of Revenue	Selling General Administrative	Gross Profit	Research Development	Selling And Marketing Expenses	Net Income From Continuing Ops	Tax Provision	Net Interest Income	Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.22	0.89	0.8	0.8	0.83	-0.05	0.8	0.51	0.8	0.77	0.82	0.81	0.48	0.81	0.89	0.78	0.81	0.77	0.61	0.61	0.88
Interest Expense	0.22		0.08	0.1	0.09	0.1	0.12	0.1	0.23	0.09	0.1	0.09	0.04	0.13	0.11	-0.01	0.09	0.1	0.11	0.07	0.07	0.02
Other Operating Expenses	0.89	0.08		0.97	0.97	0.98	-0.12	0.97	0.75	0.97	0.96	0.98	0.94	0.74	0.98	0.87	0.94	0.97	0.96	0.89	0.89	0.87
Operating Income	0.8	0.1	0.97		1.0	1.0	-0.26	1.0	0.81	1.0	1.0	1.0	0.96	0.77	0.99	0.74	0.91	1.0	1.0	0.92	0.92	0.87
Ebit	0.8	0.09	0.97	1.0		1.0	-0.26	1.0	0.79	1.0	1.0	1.0	0.96	0.77	0.99	0.76	0.91	1.0	1.0	0.92	0.92	0.87
Ebitda	0.83	0.1	0.98	1.0	1.0		-0.25	1.0	0.78	1.0	0.99	1.0	0.96	0.76	0.99	0.78	0.91	1.0	0.99	0.91	0.91	0.88
Total Operating Expenses	-0.05	0.12	-0.12	-0.26	-0.26	-0.25		-0.25	-0.15	-0.26	-0.25	-0.23	-0.46	-0.15	-0.13	-0.03	0.02	-0.25	-0.26	-0.19	-0.19	-0.38
Income Before Tax	0.8	0.1	0.97	1.0	1.0	1.0	-0.25		0.81	1.0	1.0	1.0	0.96	0.78	0.99	0.75	0.91	1.0	1.0	0.93	0.93	0.86
Total Other Income Expense Net	0.51	0.23	0.75	0.81	0.79	0.78	-0.15	0.81		0.79	0.81	0.8	0.75	0.7	0.8	0.4	0.74	0.8	0.79	0.81	0.81	0.63
Net Income	0.8	0.09	0.97	1.0	1.0	1.0	-0.26	1.0	0.79		0.99	1.0	0.96	0.79	0.99	0.78	0.91	1.0	1.0	0.93	0.93	0.87
Income Tax Expense	0.77	0.1	0.96	1.0	1.0	0.99	-0.25	1.0	0.81	0.99		0.99	0.95	0.78	0.99	0.72	0.91	1.0	1.0	0.93	0.93	0.84
Total Revenue	0.82	0.09	0.98	1.0	1.0	1.0	-0.23	1.0	0.8	1.0	0.99		0.96	0.77	0.99	0.78	0.92	1.0	0.99	0.92	0.92	0.87
Cost Of Revenue	0.81	0.04	0.94	0.96	0.96	0.96	-0.46	0.96	0.75	0.96	0.95	0.96		0.71	0.92	0.77	0.84	0.96	0.95	0.86	0.86	0.92
Selling General Administrative	0.48	0.13	0.74	0.77	0.77	0.76	-0.15	0.78	0.7	0.79	0.78	0.77	0.71		0.78	0.55	0.71	0.79	0.8	0.92	0.92	0.5
Gross Profit	0.81	0.11	0.98	0.99	0.99	0.99	-0.13	0.99	0.8	0.99	0.99	0.99	0.92	0.78		0.76	0.94	0.99	0.99	0.93	0.93	0.84
Research Development	0.89	-0.01	0.87	0.74	0.76	0.78	-0.03	0.75	0.4	0.78	0.72	0.78	0.77	0.55	0.76		0.77	0.77	0.74	0.63	0.63	0.79
Selling And Marketing Expenses	0.78	0.09	0.94	0.91	0.91	0.91	0.02	0.91	0.74	0.91	0.91	0.92	0.84	0.71	0.94	0.77		0.91	0.91	0.87	0.87	0.77
Net Income From Continuing Ops	0.81	0.1	0.97	1.0	1.0	1.0	-0.25	1.0	0.8	1.0	1.0	1.0	0.96	0.79	0.99	0.77	0.91		1.0	0.93	0.93	0.87
Tax Provision	0.77	0.11	0.96	1.0	1.0	0.99	-0.26	1.0	0.79	1.0	1.0	0.99	0.95	0.8	0.99	0.74	0.91	1.0		0.94	0.94	0.84
Net Interest Income	0.61	0.07	0.89	0.92	0.92	0.91	-0.19	0.93	0.81	0.93	0.93	0.92	0.86	0.92	0.93	0.63	0.87	0.93	0.94		1.0	0.67
Interest Income	0.61	0.07	0.89	0.92	0.92	0.91	-0.19	0.93	0.81	0.93	0.93	0.92	0.86	0.92	0.93	0.63	0.87	0.93	0.94	1.0		0.67
Reconciled Depreciation	0.88	0.02	0.87	0.87	0.87	0.88	-0.38	0.86	0.63	0.87	0.84	0.87	0.92	0.5	0.84	0.79	0.77	0.87	0.84	0.67	0.67

Click cells to compare fundamentals

Pro Medicus Account Relationship Matchups

Pro Medicus income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	7.7M	7.2M	7.3M	7.9M	8.5M	8.9M
Interest Expense	5K	538K	649K	386K	347.4K	687.2K
Other Operating Expenses	26.8M	25.5M	31.1M	41.0M	49.2M	51.7M
Operating Income	30.1M	42.4M	62.4M	83.9M	112.2M	117.8M
Ebit	30.1M	42.9M	63.1M	86.1M	112.3M	117.9M
Ebitda	37.7M	50.1M	70.4M	94.1M	120.8M	126.8M
Total Operating Expenses	5.9M	4.3M	7.9M	8.5M	10.1M	9.6M
Income Before Tax	30.0M	42.9M	63.1M	86.1M	116.5M	122.3M
Total Other Income Expense Net	(46K)	493K	693K	2.0M	4.3M	4.5M
Net Income	23.1M	30.9M	44.4M	60.6M	82.8M	86.9M
Income Tax Expense	6.9M	12.0M	18.6M	25.5M	33.7M	35.4M
Total Revenue	56.8M	67.9M	93.5M	124.9M	161.5M	169.6M
Cost Of Revenue	20.9M	21.2M	23.2M	32.5M	39.2M	41.2M
Net Income Applicable To Common Shares	23.1M	30.9M	44.4M	60.6M	69.7M	73.2M
Selling General Administrative	1.8M	2.0M	2.2M	2.2M	30.4M	31.9M
Gross Profit	35.9M	46.7M	70.3M	92.4M	122.3M	128.4M
Research Development	6.8M	6.4M	6.5M	7.1M	8.2M	8.6M
Selling And Marketing Expenses	1.5M	321K	1.9M	2.5M	2.9M	3.0M
Net Income From Continuing Ops	23.1M	30.9M	44.4M	60.6M	82.8M	86.9M
Tax Provision	6.9M	12.0M	18.6M	25.5M	33.7M	35.4M
Net Interest Income	172K	180K	649K	2.4M	4.8M	5.1M
Interest Income	172K	180K	649K	2.4M	4.8M	5.1M
Reconciled Depreciation	7.7M	7.2M	7.3M	7.9M	8.5M	7.4M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Pro Stock Analysis

When running Pro Medicus' price analysis, check to measure Pro Medicus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pro Medicus is operating at the current time. Most of Pro Medicus' value examination focuses on studying past and present price action to predict the probability of Pro Medicus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pro Medicus' price. Additionally, you may evaluate how the addition of Pro Medicus to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC